A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases
A "Classic" Ketogenic Diet as a Complementary Therapeutic Management on Patients With High-grade Gliomas and Brain Metastases.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Arezina N. Kasti, RD
- Phone Number: +30 +306942917860
- Email: kastiare@yahoo.gr
Study Contact Backup
- Name: Evangelos K. Papadopoulos, MD
- Phone Number: +30 6936251274
- Email: neuroevan@yahoo.gr
Study Locations
-
-
-
Athens, Greece, 12462
- Recruiting
- Attikon University General Hospital
-
Contact:
- Evangelos K. Papadopoulos, MD
- Phone Number: +30 6936251274
- Email: neuroevan@yahoo.gr
-
Contact:
- Arezina N. Kasti, RD
- Phone Number: +30 2105832575
- Email: kastiare@yahoo.gr
-
-
Athens
-
Chaidari, Athens, Greece, 12461
- Recruiting
- Arezina Kasti
-
Contact:
- Arezina N. Kasti, RD
- Phone Number: +30 +306942917860
- Email: kastiare@yahoo.gr
-
Contact:
- Evangelos K. Papadopoulos, MD
- Phone Number: +30 6936251274
- Email: neuroevan@yahoo.gr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-80
- Karnofsky Performance Score of 50 or more.
- Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.
- Normal function of liver and kidneys
- Ability to sign informed consent form
Exclusion Criteria:
- Diabetes mellitus
- Life expectancy >3 months
- Inability to adhere to diet
- Inability to give informed consent form
- Cholecystectomy last 1 year (before the study entry)
- Diagnosis of genetic disorder of fat metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Classic Ketogenic Diet
Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.
|
Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits.
Training will take place about diet, meal planning, and ketones/glucose monitoring.
The dietitian will follow the patient throughout treatment.
Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study.
Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival
Time Frame: Participants will be followed from date of randomization until the date of death from any cause, assessed up to 36 months.
|
Participants will be followed from date of randomization until the date of death from any cause, assessed up to 36 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to progression
Time Frame: 2 years
|
2 years
|
|
|
Changes in brain tumor size
Time Frame: 2 years, Baseline, 3, 6, 12, and 24 months
|
MRI (Magnetic Resonance Imaging) will be used to measure changes in tumor size (cm^2)
|
2 years, Baseline, 3, 6, 12, and 24 months
|
|
Assessment of Quality of life using FACT-BR (version 4) survey
Time Frame: Baseline, 3, 6, 12 months
|
50-item FACT-Br (Functional Assessment of Cancer Therapy - Brain) is a self-report and interview when applicable questionnaire used to assess quality of life, which includes domains such as Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Brain Cancer Subscale.
Each of them is rated based on the Likert scale from 1 to 5.
|
Baseline, 3, 6, 12 months
|
|
Functional impairment will be assessed with the Karnofsky Performance Scale
Time Frame: Baseline, 3, 6, 12 months
|
The scoring is assigned by a health professional based on the hierarchical scale: 100=normal, no evidence of disease, while 10=death.
Intermediate or decimal scores can be assigned.
|
Baseline, 3, 6, 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Efstathios Boviatsis, MD, University General Hospital Attikon
Publications and helpful links
General Publications
- Ebrahimpour-Koujan S, Shayanfar M, Benisi-Kohansal S, Mohammad-Shirazi M, Sharifi G, Esmaillzadeh A. Adherence to low carbohydrate diet in relation to glioma: A case-control study. Clin Nutr. 2019 Dec;38(6):2690-2695. doi: 10.1016/j.clnu.2018.11.023. Epub 2018 Nov 30.
- Thomas JG, Veznedaroglu E. Ketogenic Diet for Malignant Gliomas: a Review. Curr Nutr Rep. 2020 Sep;9(3):258-263. doi: 10.1007/s13668-020-00332-2.
- Sargaco B, Oliveira PA, Antunes ML, Moreira AC. Effects of the Ketogenic Diet in the Treatment of Gliomas: A Systematic Review. Nutrients. 2022 Feb 27;14(5):1007. doi: 10.3390/nu14051007.
- Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71-95. doi: 10.1016/B978-0-12-802997-8.00005-0.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplastic Processes
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Neoplasm Metastasis
- Glioma
- Brain Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- ΕΒΔ246/14-04-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.